Virtual Library
Start Your Search
P. Paximadis
Author of
-
+
P3.03 - Poster Session/ Treatment of Locoregional Disease – NSCLC (ID 214)
- Event: WCLC 2015
- Type: Poster
- Track: Treatment of Locoregional Disease – NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P3.03-034 - Utility of Surveillance Imaging in Detection of Recurrence in Treated Stage III NSCLC Patients (ID 2766)
09:30 - 09:30 | Author(s): P. Paximadis
- Abstract
Background:
About a third of newly diagnosed NSCLC patients have stage III disease at diagnosis, of whom, a quarter achieve long term survival. The current recommendation of National Comprehensive Cancer Network (NCCN) for surveillance following completion of therapy is to perform CT scan of the chest every 6-12 months for 2 years. However, it is unclear if strategy of surveillance scans is superior in detecting recurrences as compared to the strategy of scans done for symptoms suggestive of disease progression. We conducted a retrospective analysis of stage III NSCLC at our institution to estimate the rate of detection of recurrence in scans performed for symptomatic worsening, in patients on surveillance scans.
Methods:
This study is a single institutional, retrospective, review utilizing the Karmanos Cancer Institute lung cancer database established in 2010. Inclusion criteria: stage III lung cancer patients who had completed therapy and who were treated between 2011 and 2013. Exclusion criteria: inadequate documentation and those who were not eligible for treatment based on clinician or patient preference. Patients were followed until progression or last assessment. The primary objective was to estimate the percentage of patients who had documented tumor recurrence on a surveillance scan.
Results:
Fifty four patients met the eligibility criteria. Mean age was 61 years (40-80), 34% were males; 44% were Caucasians and 39% were African-Americans; 85% were current or former smokers. Histology at diagnosis was adenocarcinoma in 67% and squamous cell in 31%, the remaining were large cell and poorly differentiated. Thirty-seven (69%) patients received chemotherapy and radiation, 12 (22%) received surgery with chemotherapy and radiation, and 5 (9%) received surgery and chemotherapy. The median follow up following completion of treatment was 18 months. Eighteen (33%) patients have had disease recurrence, with 11 (20%) recurrences within 1 year following completion of therapy. Of all 18 patients with recurrences, 17 (98%) were detected on surveillance scans. Only 1 (2%; 95% CI: 0-10%) recurrence was detected on scans obtained for worsening symptoms.
Conclusion:
In this retrospective analysis in stage III NSCLC patients who had completed therapy, except one case, all of the recurrences were detected on surveillance scans, strongly suggesting that routine surveillance scans provide clinical utility.
